About 200 reports

Psoriatic arthritis

4546 5000 3864
  • US PSORIATIC ARTHRITIS TREATMENT RATE AND USAGE OF BIOLOGIC THERAPIES, BY DISEASE SEVERITY AND LINE OF THERAPY
  • MEAN PERCENTAGE OF PSORIATIC ARTHRITIS PATIENTS RECEIVING EACH BIOLOGIC THERAPY, BY SEVERITY AND LINE OF THERAPY, 2013

Humira and Enbrel will remain the dominant therapies in psoriatic arthritis (PsA), despite significant pressure from the launch of biosimilars. This report addresses the following questions: - To what extent will the launch of cheaper biosimilars affect sales of the longstanding tumor necrosis factor (TNF)-alpha inhibitors? -...

  • Biological Therapy
  • United States
  • Amgen Inc.
  • Celgene Corporation
  • Johnson & Johnson

The multi-modality treatment of cancer may include surgery, chemotherapy, biological therapy, or radiation therapy.

  • Biological Therapy
  • United States
  • Carl Zeiss Meditec AG
  • Eckert & Ziegler AG
  • Varian Medical Systems, Inc.

Whether they would be willing to sacrifice any benefit in exacerbation reduction for improved secondary considerations (such as FEV-## asthma control scores and ACQ-## asthma control scores) in a typical severe asthma patient being treated with a biologic therapy?

  • Asthma
  • Biological Therapy
  • Therapy
  • United States
  • Forecast

EXPERT OPINION ON BIOLOGICAL THERAPY; ##(##): ##-##.

  • Biological Therapy
  • United States
  • Athersys, Inc.
  • Fresenius Group
  • GlobalData's company

They were asked to rank seven therapy areas according to the number of marketed therapies these would experience compared to one another (with ## having the lowest number of marketed therapies and ## the highest).

  • Biological Therapy
  • Cell Therapy
  • Stem Cell
  • Stem Cell Therapy
  • United States

Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer.

  • Biological Therapy
  • United States
  • Advantagene, Inc.
  • Celsion Corporation
  • Takara Bio Inc.

In Europe, the EC is one of the governmental organization that funds for biologicals research and development.

  • Biological Therapy
  • United States
  • Biogen Idec Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • 16. INTERVIEW TRANSCRIPTS

FIGURE ##. ## PRESENTS THE MOST PROMINENT VIRAL VECTORS THAT ARE BEING UTILIZED FOR DEVELOPING GENE THERAPIES TARGETING VARIOUS ONCOLOGICAL INDICATIONS. ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Biological Therapy
  • United States
  • Company
  • Demand
  • Market Size

CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY CAR-T CELL THERAPIES FORM ONE OF THE MAJOR ARMS OF THE EXPERIMENTAL BIOLOGICAL ANTI-CANCER THERAPIES IN THE PHARMACEUTICAL MARKET.

  • Biological Therapy
  • United States
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG
  • IN NORTH AMERICA

IT CURRENTLY OPERATES AS ONE OF THE WHOLLY OWNED SUBSIDIARIES OF COBRA BIOLOGICS HOLDING.

  • Biological Therapy
  • DNA
  • Gene Therapy
  • Viral Vector
  • United States
  • 4) Cancer Gene Therapy in the 8MM: History and Current Landscape

I think in terms of its biological potential, treatment potential, I think it is very, very big in other cancers.

  • Biological Therapy
  • Biotechnology
  • Gene Therapy
  • Therapy
  • United States

SAMSUNG BIOLOGICS' PLANT ### CAME INTO OPERATION IN MAY 2011.

  • Biological Therapy
  • North America
  • United States
  • Biologics, Inc.
  • Catalent Pharma Solutions, Inc.

OTHER BIOLOGICS INCLUDE GENE THERAPIES, FUSION PROTEINS, UNSPECIFIED BIOLOGICAL MOLECULES INCLUDING IMETELSTAT (PHASE III), ABT-## (PHASE I) AND AMC## (PHASE I).

  • Biological Therapy
  • United States
  • Demand
  • AstraZeneca PLC
  • Novartis AG

THESE TWO TRIALS WERE DESIGNED WITH ONE YEAR TREATMENT DURATION.

  • Biological Therapy
  • Biopharmaceutical
  • Biosimilar
  • Pharmaceutical
  • United States
  • highlights the forecasted growth of the overall CAR-T cells market spanning
  • T-CELL RECEPTOR (TCR) THERAPIES

NOVEL TREATMENTS FORM ANOTHER ARM OF THE AVAILABLE THERAPIES WHICH INCLUDES THE BIOLOGIC THERAPY.

  • Biological Therapy
  • United States
  • Cellectis S.A.
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.

It is comprised of the delivery of a therapeutic gene, protein Phosphatase-## Inhibitor-## (I- ##) with the use of Biological NanoParticles (BNPs) and the Self-Complementary Vector Technology.

  • Biological Therapy
  • United States
  • Bioheart, Inc.
  • Celladon Corporation
  • GlaxoSmithKline plc

" Based on those results, we will determine whether we will investigate this biologic therapy in a longer study, or perhaps consider studying a combination therapy that involves more than one biologic therapy. "

  • Biological Therapy
  • Pharmaceutical
  • Therapy
  • United States
  • World

The CBER regulates biologics including allergenic extracts blood and blood components, gene therapy products, devices and test kits human tissue and cellular products used in transplantation and vaccines.

  • Biological Therapy
  • Cell Therapy
  • United States
  • Market Size
  • Selexis SA

After ## week without therapy, combined therapy is resumed at the beginning of week ##.

  • Biological Therapy
  • Breast Cancer
  • Therapy
  • Transplantation
  • United States

The company' s product portfolio includes biologics, prescription pharmaceuticals and vaccines.

  • Biological Therapy
  • Pharmaceutical
  • Therapy
  • United States
  • World

This results in cost savings for patients, with increased access to high-cost biologic treatments at lower prices.

  • Biological Therapy
  • Biopharmaceutical
  • Biosimilar
  • North America
  • United States

After ## week without therapy, combined therapy is resumed at the beginning of week ##.

  • Biological Therapy
  • Breast Cancer
  • Therapy
  • Transplantation
  • United States

FDA to obtain " fast track" designation for CVBT-##B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-## (FGF-##).

  • Biological Therapy
  • Therapy
  • Type 2 Diabetes
  • Wound Care
  • United States

After ## week without therapy, combined therapy is resumed at the beginning of week ##.

  • Biological Therapy
  • Breast Cancer
  • Therapy
  • United States
  • Product Initiative
  • MERGER

GlobalData Region North America Asia-Pacific Europe Middle East and Africa South and Central America No. of Deals ## ## ## ## ## Deal Value (US$ million) ##. ## NA NA NA NA BioCardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

  • Biological Therapy
  • United States
  • Company
  • Deals & Alliance
  • BioCardia, Inc.
  • MERGER

GlobalData Region North America Asia-Pacific Europe Middle East and Africa South and Central America No. of Deals ## ## ## ## ## Deal Value (US$ million) ##. ## NA NA NA NA BioCardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

  • Biological Therapy
  • United States
  • Company
  • Deals & Alliance
  • BioCardia, Inc.

It is indicated for the treatment of complex perianal fistulas in adult patients with nonactive/ mildly active luminal Crohn' s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.

  • Biological Therapy
  • Healthcare
  • Pharmaceutical
  • United States
  • TiGenix NV

TECHNIQUES ##. ## BIOMATERIALS ##. ##. ## BIOLOGICALLY DERIVED BIOMATERIALS Chapter ## ##-## ##. ##. ##. ## COLLAGEN Tissue Engineering and Cellular Therapy Tools and Techniques COLLAGEN IS A PROVEN MATERIAL FROM THE STANDPOINT OF BIOCOMPATIBILITY; IT IS WIDELY USED IN CAS

  • Biological Therapy
  • Cell Therapy
  • North America
  • United States
  • Athersys, Inc.
  • MAY 10, 2018: CENTERS FOR MEDICARE AND MEDICAID SERVICES APPROVES REIMBURSEMENT FOR BIOCARDIA'S CARDIAMP CELL THERAPY IN PIVOTAL CLINICAL TRIAL STUDYING SECOND INDICATION IN CHRONIC MYOCARDIAL ISCHEMIA

ABOUT BIOCARDIA® BIOCARDIA, INC., HEADQUARTERED IN SAN CARLOS, CA, IS DEVELOPING REGENERATIVE BIOLOGIC THERAPIES TO TREAT CARDIOVASCULAR DISEASE.

  • Biological Therapy
  • Cardiovascular Disease
  • Cell Therapy
  • Heart Failure
  • United States

Business Questions • In February 2018, AbbVie presented positive results from the UltiMMa-## and UltiMMa-## Phase III clinical trials, illustrating the superiority of interleukin-## (IL-##) inhibitor risankizumab compared with marketed biological therapy Stelara (ustekinumab

  • Autoimmune Disease
  • Biological Therapy
  • Therapy
  • United States
  • Product Initiative